1. < Home

PD-L1

Pharmacokinetics (PK) of Tiragolumab in First-in-Human Study in Patients With Mixed Solid Tumors (GO30103)

Garralda E, Oh DY, Italiano A, Bedard PL, Delord JP, Calvo E, LoRusso P, Wainberg Z, Cervantes A, Rodriguez-Vida A, Shemesh CS, Sane R, Mendus[...]

By sjmartinez • December 18, 2023
Bintrafusp Alfa Versus Pembrolizumab in Patients With Treatment-Naive, Programmed Death-Ligand 1-High Advanced NSCLC: A Randomized, Open-Label, Phase 3 Trial

Cho BC, Lee JS, Wu YL, Cicin I, Dols MC, Ahn MJ, Cuppens K, Veillon R, Nadal E, Dias JM, Martin C, Reck M, Garon[...]

By sjmartinez • November 28, 2023
Extracellular vesicles as biomarkers for AIDS-associated non-Hodgkin lymphoma risk

Martínez LE, Magpantay LI, Guo Y, Hegde P, Detels R, Hussain SK, Epeldegui M. Extracellular vesicles as biomarkers for AIDS-associated non-Hodgkin lymphoma risk. Front Immunol.[...]

By sjmartinez • October 9, 2023
Bintrafusp alfa versus pembrolizumab in patients with treatment-naive, PD-L1-high advanced non-small cell lung cancer: a randomized, open-label, phase 3 trial

Cho BC, Lee JS, Wu YL, Cicin I, Dols MC, Ahn MJ, Cuppens K, Veillon R, Nadal E, Dias JM, Martin C, Reck M, Garon[...]

By sjmartinez • August 20, 2023
Role of PD-1 Inhibitors in the Treatment of Esophagogastric Adenocarcinoma: Patient Selection and Reported Outcomes

Epistola R, Sperandio R, Wainberg Z, Iqbal S, Chao J. Role of PD-1 Inhibitors in the Treatment of Esophagogastric Adenocarcinoma: Patient Selection and Reported Outcomes.[...]

By sjmartinez • March 28, 2023
Comparison of the tumor immune microenvironment and checkpoint blockade biomarkers between stage III and IV non-small cell lung cancer

Gao Y, Stein MM, Kase M, Cummings AL, Bharanikumar R, Lau D, Garon EB, Patel SP. Comparison of the tumor immune microenvironment and checkpoint blockade[...]

By sjmartinez • January 26, 2023